Literature DB >> 30078111

N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents.

Ovsanna Leyfer1, Aubrey Carpenter2, Donna Pincus3.   

Abstract

Panic disorder (PD) can result in significant functional impairment. Studies of cognitive behavioral therapy (CBT) for PD have demonstrated response rates ranging between 38 and 65%. D-cycloserine (DCS), a partial NMDA agonist, may enhance the effects of exposure-based therapy for PD in adults; however, no studies have examined its effect in adolescents with PD. This study examined the feasibility and acceptability of the use of DCS to augment intensive CBT for PD in adolescents. Twenty-four adolescents (ages 12-17) participated in this randomized, double-blinded, placebo-controlled trial, to compare CBT + DCS to CBT + placebo. The results demonstrated the feasibility and acceptability of the treatment to participants. No significant differences were found between the two groups, but both groups showed significant improvement. This is the first investigation of DCS in the treatment of PD in adolescents and it provides initial support for a more extensive study of DCS augmentation of CBT among adolescents with PD.

Entities:  

Keywords:  Adolescents; Anxiety; Cognitive-behavioral therapy; D-Cycloserine; Outcome; Panic disorder

Mesh:

Substances:

Year:  2019        PMID: 30078111     DOI: 10.1007/s10578-018-0837-1

Source DB:  PubMed          Journal:  Child Psychiatry Hum Dev        ISSN: 0009-398X


  39 in total

Review 1.  D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse.

Authors:  Stefan G Hofmann
Journal:  Depress Anxiety       Date:  2014-03       Impact factor: 6.505

Review 2.  D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update.

Authors:  Stefan G Hofmann; Alice T Sawyer; Anu Asnaani
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Multicenter collaborative panic disorder severity scale.

Authors:  M K Shear; T A Brown; D H Barlow; R Money; D E Sholomskas; S W Woods; J M Gorman; L A Papp
Journal:  Am J Psychiatry       Date:  1997-11       Impact factor: 18.112

Review 4.  D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.

Authors:  David Mataix-Cols; Lorena Fernández de la Cruz; Benedetta Monzani; David Rosenfield; Erik Andersson; Ana Pérez-Vigil; Paolo Frumento; Rianne A de Kleine; JoAnn Difede; Boadie W Dunlop; Lara J Farrell; Daniel Geller; Maryrose Gerardi; Adam J Guastella; Stefan G Hofmann; Gert-Jan Hendriks; Matt G Kushner; Francis S Lee; Eric J Lenze; Cheri A Levinson; Harry McConnell; Michael W Otto; Jens Plag; Mark H Pollack; Kerry J Ressler; Thomas L Rodebaugh; Barbara O Rothbaum; Michael S Scheeringa; Anja Siewert-Siegmund; Jasper A J Smits; Eric A Storch; Andreas Ströhle; Candyce D Tart; David F Tolin; Agnes van Minnen; Allison M Waters; Carl F Weems; Sabine Wilhelm; Katarzyna Wyka; Michael Davis; Christian Rück; Margaret Altemus; Page Anderson; Judith Cukor; Claudia Finck; Gary R Geffken; Fabian Golfels; Wayne K Goodman; Cassidy Gutner; Isobel Heyman; Tanja Jovanovic; Adam B Lewin; Joseph P McNamara; Tanya K Murphy; Seth Norrholm; Paul Thuras
Journal:  JAMA Psychiatry       Date:  2017-05-01       Impact factor: 21.596

5.  The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans.

Authors:  Oezguer A Onur; Thomas E Schlaepfer; Juraj Kukolja; Andreas Bauer; Haang Jeung; Alexandra Patin; David-Marian Otte; N Jon Shah; Wolfgang Maier; Keith M Kendrick; Gereon R Fink; René Hurlemann
Journal:  Biol Psychiatry       Date:  2010-03-20       Impact factor: 13.382

6.  A psychometric evaluation of the panic disorder severity scale for children and adolescents.

Authors:  R Meredith Elkins; Donna B Pincus; Jonathan S Comer
Journal:  Psychol Assess       Date:  2013-12-02

7.  D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions.

Authors:  Jasper A J Smits; David Rosenfield; Michael W Otto; Luana Marques; Michelle L Davis; Alicia E Meuret; Naomi M Simon; Mark H Pollack; Stefan G Hofmann
Journal:  J Psychiatr Res       Date:  2013-07-16       Impact factor: 4.791

8.  Economic costs of full-blown and subthreshold panic disorder.

Authors:  Neeltje Batelaan; Filip Smit; Ron de Graaf; Anton van Balkom; Wilma Vollebergh; Aartjan Beekman
Journal:  J Affect Disord       Date:  2007-04-26       Impact factor: 4.839

9.  Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.

Authors:  Lara J Farrell; Allison M Waters; Mark J Boschen; Laetitia Hattingh; Harry McConnell; Ella L Milliner; Nigel Collings; Melanie Zimmer-Gembeck; Doug Shelton; Thomas H Ollendick; Chris Testa; Eric A Storch
Journal:  Depress Anxiety       Date:  2013-05-30       Impact factor: 6.505

10.  Neuroenhancement of Exposure Therapy in Anxiety Disorders.

Authors:  Stefan G Hofmann; Elizabeth A Mundy; Joshua Curtiss
Journal:  AIMS Neurosci       Date:  2015
View more
  3 in total

1.  Predictors of Treatment Satisfaction Among Adolescents Following an Intensive Cognitive-Behavioral Intervention for Panic Disorder.

Authors:  Maya Nauphal; Ovsanna T Leyfer; Erin F Ward-Ciesielski; Donna B Pincus
Journal:  Child Psychiatry Hum Dev       Date:  2020-09-03

Review 2.  Optimising Exposure for Children and Adolescents with Anxiety, OCD and PTSD: A Systematic Review.

Authors:  Hannah Plaisted; Polly Waite; Kate Gordon; Cathy Creswell
Journal:  Clin Child Fam Psychol Rev       Date:  2021-02-06

Review 3.  A Systematic Review of Parental Involvement in Cognitive Behavioural Therapy for Adolescent Anxiety Disorders.

Authors:  Jessica Louise Cardy; Polly Waite; Francesca Cocks; Cathy Creswell
Journal:  Clin Child Fam Psychol Rev       Date:  2020-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.